Summary of Late-Breaking Drug Trials at ACC.25 , major breakthroughs in cardiovascular pharmacology were presented
Summary of Late-Breaking Drug Trials at ACC.25 , major breakthroughs in cardiovascular pharmacology were presented:
• Semaglutide (GLP-1 RA):
• STRIDE trial: Showed significant improvement in symptoms and walking distance in patients with peripheral artery disease (PAD) — first such therapy in over 20 years. This marks the first major therapeutic advance in the treatment of PAD since cilostazol and supervised exercise therapy introduced decades ago.
• SOUL trial: Oral semaglutide showed modest cardiovascular benefits compared to the injectable formulations ; still important for needle-averse patients.
• Api-CAT trial:
• Demonstrated that low-dose apixaban in cancer patients with VTE offers similar efficacy to standard dose but with lower bleeding risk.
• WARRIOR trial:
• Intensive medical therapy in women with INOCA was neutral in outcomes, but emphasized continued use of statins and ACEs/ARBs, and highlighted the need for further research.
• Lorundrostat:
• A new aldosterone synthase inhibitor showed strong blood pressure reduction in resistant hypertension (Phase 2B), with promise for future use.
• REVERSE-IT trial:
• Bentracimab, a reversal agent for ticagrelor, showed effectiveness in managing major bleeding — offering a critical safety option.
Quote from Dr. Richard Kovacs (ACC CMO):
This year’s trials bring long-awaited tools for underserved conditions like PAD and resistant hypertension.